Compare EHC & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EHC | QGEN |
|---|---|---|
| Founded | 1983 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7B | 10.2B |
| IPO Year | 1994 | 1998 |
| Metric | EHC | QGEN |
|---|---|---|
| Price | $106.49 | $41.05 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 8 |
| Target Price | ★ $143.29 | $50.26 |
| AVG Volume (30 Days) | 866.9K | ★ 1.3M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | 0.71% | ★ 5.84% |
| EPS Growth | ★ 24.22 | N/A |
| EPS | ★ 5.54 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.33 | $8.18 |
| Revenue Next Year | $8.14 | $5.71 |
| P/E Ratio | ★ $19.20 | $24.01 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $92.77 | $38.80 |
| 52 Week High | $127.99 | $57.82 |
| Indicator | EHC | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 59.58 | 44.85 |
| Support Level | $105.88 | $38.80 |
| Resistance Level | $109.21 | $48.53 |
| Average True Range (ATR) | 2.44 | 0.79 |
| MACD | 0.55 | 0.34 |
| Stochastic Oscillator | 81.03 | 53.32 |
Encompass Health Corp provides post-acute healthcare services in the United States through a network of inpatient rehabilitation hospitals, which is the company's sole segment. Inpatient rehabilitation contributes the majority of the firm's revenue and provides specialized rehabilitative treatment through a network of inpatient hospitals. The company's inpatient rehabilitation hospitals provide a higher level of rehabilitative care to patients who are recovering from conditions such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).